Reta (GLP3) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors for advanced obesity, diabetes, and metabolic research. Phase 2 trials show up to 24.2% mean weight loss at 48 weeks with sustained effects.

Receptor Mechanism

Reta activates GLP-1R for appetite suppression and glycemic control, GIPR for insulin secretion, and GCGR for energy expenditure and lipolysis. Cryo-EM structures reveal a helical peptide binding with receptor-specific ECL1/ECL2 interactions for potent triple agonism.

Research Benefits

Delivers superior weight reduction (14-24%), HbA1c drops (-0.91%), liver fat resolution (>80% at high doses), and improvements in BP, lipids, and waist circumference. Enhances NASH resolution, insulin sensitivity, and cardiometabolic markers without plateau in trials.

Product Specifications

• Purity: 99%+ research-grade lyophilized powder.

• Molecular Design: ~39-aa synthetic peptide mimicking incretins/glucagon.

• Applications: In-vivo obesity/T2D models; weekly dosing.

• Storage: -20°C lyophilized.